Table 1.

Included studies.

Author, year	Study population	Country	No. of patients	Antibiotic	Primary outcome	Secondary outcomes	Control group
Kalra et al., 2015 5	Ischemic and hemorrhagic stroke patients with dysphagia	United Kingdom	1217	Local protocol	Post-stroke pneumonia in the first 14 days after stroke	Functional outcome (mRS) at 90 days, mortality, adverse events	Standard care
Westen-dorp et al., 2015 8	Ischemic and hemorrhagic stroke patients	The Nether-lands	2538	Ceftriaxone	Functional outcome at 3 months on the mRS	Infections, pneumonia, mortality, adverse events	Standard care
Harms et al., 2008 4	Patients with ischemic stroke (NIHSS>11) in middle cerebral artery territory	Germany	79	Moxifloxacin	Infection within 11 days after stroke	Neurological outcome (mRS), survival, immune-depression, induction of bacterial resistance	Placebo
Chamorro et al., 2005 3	Ischemic and hemorrhagic stroke patients	Spain	136	Levo-floxacin	Infection within 7 days after stroke	Neurological outcome (mRS) and mortality at 90 days	Placebo
Chang et al., 2017 23	Hemorrhagic stroke patients	USA	20	Minocycline	Adverse events	Change in serial NIHSS score, hematoma volume, MMP-9 measurements, 3-month functional outcome (mRS) and mortality	Placebo
Fouda et al., 2017 24	Hemorrhagic stroke patients	USA	16	Minocycline	Serum concentrations of minocycline	ICH volume, inflammatory parameters	Standard care
Amiri-Nikpour et al., 2015 25	Ischemic stroke patients	Iran	53	Minocycline	NIHSS at 3 months	NIHSS at 30, 60 days	Standard care
Kohler et al., 2013 26	Ischemic and hemorrhagic stroke patients	Australia	92	Minocycline	Survival free of handicap (mRS ≤2) at day 90	NIHSS at day 7, Barthel index at 90 days	Standard care
Blacker et al., 2013 27	Ischemic stroke patients that received thrombolysis	Australia	46	Minocycline	Hemorrhagic transformation on CT-scan	—	Standard care